Table of contents

Clinical/translational cancer immunotherapy

• Original research: Six-week oral prednisolone therapy for immune-related pneumonitis: a single-arm phase II study (27 July, 2023)

  Masato Karayama, Naoki Inui, Yusuke Inoue, Hideki Yasui, Hironao Hozumi, Yuzo Suzuki, Kazuki Furuhashi, Tomoyuki Fujisawa, Noriyuki Enomoto, Kazuhiro Asada, Tomohiro Uto, Masato Fujii, Takashi Matsui, Shun Matsuura, Dai Hashimoto, Mikio Toyoshima, Masaki Ikeda, Hiroyuki Matsuda, Nao Inami, Yusuke Kaida, Satoshi Funayama, Shintaro Ichikawa, Satoshi Goshima, Takafumi Suda
• Original research: Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study (24 July, 2023)

  Arielle Elkrief, Joao M Victor Alessi, Biagio Ricciuti, Samantha Brown, Hira Rizvi, Isabel R Preeshagul, Xinan Wang, Federica Pecci, Alessandro Di Federico, Giuseppe Lamberti, Jacklynn V Egger, Jamie E Chaft, Charles M Rudin, Gregory J Riely, Mark G Kris, Marc Ladanyi, Yuan Chen, Matthew D Hellmann, Ronglai Shen, Mark M Awad, Adam J Schoenfeld
• Original research: IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models (21 July, 2023)

  Marjolein C Stip, Mitchell Evers, Maaike Nederend, Chilam Chan, Karli R Reiding, Mirjam J Damen, Albert J R Heck, Sofia Koustoulidou, Ruud Ramakers, Gerard C Krijger, Remmert de Roos, Edouard Souteyrand, Annelisa M Cornel, Miranda P Dierselhuis, Marco Jansen, Mark de Boer, Thomas Valerius, Geert van Tetering, Jeanette H W Leusen, Friederike Meyer-Wentrup
• Original research: IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation (21 July, 2023)

  Elisa A Rozeman, Judith M Versluis, Karolina Sikorska, Esmée P Hoefsmit, Petros Dimitriadis, Disha Rao, Ruben Lacroix, Lindsay G Grijpink-Ongering, Marta Lopez-Yurda, Birthe C Heeres, Bart A van de Wiel, Claudie Flohil, Aysegul Sari, Stijn W T P J Heijmink, Daan van den Broek, Annegien Broeks, Jan Willem B de Groot, Marieke A Vollebergh, Sofie Wilgenhof, Johannes V van Thienen, John B A G Haanen, Christian U Blank
• Original research: Immune suppressive microenvironment in liver metastases contributes to organ-specific response of immunotherapy in advanced non-small cell lung cancer (18 July, 2023)

  Jia-Yi Deng, Qing Gou, Lingling Yang, Zhi-Hong Chen, Ming-Yi Yang, Xiao-Rong Yang, Hong-Hong Yan, Xue-Wu Wei, Jia-Qi Liu, Jian Su, Wen-Zhao Zhong, Chong-Rui Xu, Yi-Long Wu, Qing Zhou
• Original research: Dual inhibition of BTLA and PD-1 can enhance therapeutic efficacy of paclitaxel on intraperitoneally disseminated tumors (18 July, 2023)

  Wei-Zen Sun, Han-Wei Lin, Wan-Yu Chen, Chung-Liang Chien, Yen-Ling Lai, Jung Chen, Yu-Li Chen, Wen-Fang Cheng
• Original research: Impact of immune checkpoint inhibitors on atherosclerosis progression in patients with lung cancer (11 July, 2023)

  Zsofia Dora Drobni, Carlos Gongora, Jana Taron, Giselle A Suero-Abreu, Julia Karady, Hannah K Gilman, Sama Supraja, Sofia Nikolaidou, Nicolas Leeper, Béla Merkely, Pal Maurovich-Horvat, Borek Foldyna, Tomas G Neilan
• Original research: Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial (4 July, 2023)

  Mehmet Altan, Yan Wang, Juhee Song, James Welsh, Chad Tang, Nandita Guha-Thakurta, George R Blumenschein, Brett W Carter, Jeffrey S Wefel, Amol J Ghia, Debra N Yeboa, Mary Frances McAleer, Caroline Chung, Kristina D Woodhouse, Susan L McGovern, Chenyang Wang, Betty Y S Kim, Jeffrey S Weinberg, Tina M Briere, Yasir Y Elamin, Xiuning Le, Tina Cascone, Marcelo V Negrao, Ferdinandos Skoulidis, Renata Ferrarotto, John V Heymach, Jing Li
• Original research:

  Combination of cancer vaccine with CD122-biased IL-2/anti-IL-2 Ab complex shapes the stem-like effector NK and CD8⁺ T cells against tumor

  (3 July, 2023)

  Kanako Shimizu, Shogo Ueda, Masami Kawamura, Honoka Aoshima, Mikiko Satoh, Jun Nakabayashi, Shin-ichiro Fujii